



Lifeloc Reports Second Quarter 2019 Results

August 07, 2019 02:43 PM Eastern Daylight Time

WHEAT RIDGE, Colo.--(<u>BUSINESS WIRE</u>)--Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the second quarter ended June 30, 2019.

Second Quarter Highlights

Lifeloc posted quarterly net revenue of \$2.34 million resulting in quarterly net income after taxes of \$219 thousand, or \$0.09 per diluted share. These results compare to net revenue of \$2.13 million and quarterly net income of \$78 thousand, or \$0.03 per diluted share in the second quarter of 2018. Gross margin on total revenue grew to 49% versus 47% in the same quarter last year. Revenue for the quarter increased nearly 10% versus the second quarter last year. For the first six months of the 2019, net revenue was \$4.41 million and net income was \$250 thousand, versus revenue of \$4.33 million and net income of \$89 thousand for the same period last year (\$0.10 vs. \$0.04 per diluted share).

The second quarter performance benefited from the release and shipments of the second generation of our patent protected EasyCal[®] automated calibration station. This updated calibration station has expanded capabilities to calibrate our entire line of professional breathalyzers as well as RFID (Radio Frequency Identification) registration of calibration standards to further automate the process, representing a further advance of an already unique product.

"It was a strong quarter, both in top line revenue growth and bottom line earnings," said CEO Dr. Wayne Willkomm. He added, "It is great to see revenue growth and a good profit number. Both reflect the hard work that we have accomplished over the last number of years. But we are not satisfied, and we intend to continue heavy investment into our brightest growth opportunities, especially alcohol monitoring and real-time drug detection with SpinDx, the lab on a disc and the marijuana breathalyzer."

Alcohol monitoring is accomplished through our R.A.D.A.R.[®] (Real-time Alcohol Detection and Reporting) device, which is a tool to supervise offenders as an alternative to incarceration. The R.A.D.A.R. device calls for random alcohol tests, and stores the results for later retrieval by the probation officer, while onboard biometrics automatically verify the identity of the test subject. The second generation R.A.D.A.R. devices are in development with production expected later this year. R.A.D.A.R. devices and their associated monitoring services are a critical step in moving our business towards a recurring revenue model.

The brightest growth opportunity consists of our developments in real-time drug testing, including the marijuana breathalyzer and a rapid panel analysis of such drugs as heroin, cocaine, meth and others, with the SpinDx platform. Getting rapid, quantitative results for drugs of abuse, including marijuana, is a critical tool needed by law enforcement to ensure safety on our roads and in the workplace. We have demonstrated SpinDx to perform trace analysis from liquid and vapor samples in the laboratory. Our work ahead is to complete the conversion of SpinDx from a laboratory test to simple-

to-operate devices ready for deployment in the field.

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades overthe-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, <u>www.lifeloc.com/investor</u>.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our <u>SEC</u>

Condensed Balance Sheets

ASSETS

	June 30,			
		December		
	2019	31,		
CURRENT ASSETS:	(Unaudited)	2018		
Cash and cash equivalents	\$ 2,535,108	\$ 2,788,327		
Accounts receivable, net	905,762	675,136		
Inventories, net	1,946,047	1,290,607		
Income taxes receivable	-	90,629		
Prepaid expenses and other	129,581	35,155		
Total current assets	5,516,498	4,879,854		
PROPERTY AND EQUIPMENT, at cost:				
Land	317,932	317,932		
Building	1,941,414	1,928,795		
Real-time Alcohol Detection And Reporting equipment and software	569,448	569,448		
Production equipment and software	911,454	800,569		
Training courses	432,375	432,375		
Office equipment and software	246,946	241,836		
Sales and marketing equipment	219,797	219,797		
Research and development equipment and software	159,810	159,810		
Less accumulated depreciation	(1,849,978)	(1,649,203)		
Total property and equipment, net	2,949,198	3,021,359		
OTHER ASSETS:				
Patents, net	151,739	158,147		
Deposits and other	77,569	140,452		
Deferred taxes	87,485	79,869		
Total other assets	316,793	378,468		
Total assets	\$ 8,782,489	\$ 8,279,681		

Total current liabilities	1,012,297	741,385
TERM LOAN PAYABLE, net of current portion and		
debt issuance costs	1,346,989	1,369,347
DEFERRED REVENUE, net of current portion	9,561	8,212
Total liabilities	2,368,847	2,118,944
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY:		
Common stock, no par value; 50,000,000 shares		
authorized, 2,454,116 shares outstanding	4,600,867	4,597,646
Retained earnings	1,812,775	1,563,091
Total stockholders' equity	6,413,642	6,160,737
Total liabilities and stockholders' equity	\$ 8,782,489	\$ 8,279,681

Condensed Statements of Income (Unaudited)

	Three Months Ended June 30,			
REVENUES:		2019	,	2018
Product sales	\$	2,166,634	\$	2,013,790
Royalties		150,146		96,358
Rental income		20,942		19,101
Total		2,337,722		2,129,249
COST OF SALES		1,182,588		1,133,779
GROSS PROFIT		1,155,134		995,470
OPERATING EXPENSES:				
Research and development		243,369		253,229
Sales and marketing		315,539		330,657
General and administrative		295,618		296,124
Total		854,526		880,010
OPERATING INCOME		300,608		115,460
OTHER INCOME (EXPENSE):				
Interest income		7,850		4,253
Interest expense		(14,468)		(17,374)
Total		(6,618)		(13,121)
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES		293,990		102,339
(PROVISION FOR) BENEFIT FROM FEDERAL AND STATE INCOME TAXES		(75,270)		(24,210)
NET INCOME	\$	218,720	\$	78,129
NET INCOME PER SHARE, BASIC	\$	0.09	\$	0.03
NET INCOME PER SHARE, DILUTED	\$	0.09	\$	0.03
WEIGHTED AVERAGE SHARES, BASIC		2,454,116		2,454,116

Condensed Statements of Income (Unaudited)

	Six Months Ended June 30,			
REVENUES:		2019		2018
Product sales	\$	4,136,735	\$	4,136,033
Royalties		222,984		161,423
Rental income		46,764		33,702
Total		4,406,483		4,331,158
COST OF SALES		2,319,147		2,335,525
GROSS PROFIT		2,087,336		1,995,633
OPERATING EXPENSES:				
Research and development		489,168		591,555
Sales and marketing		631,922		666,058
General and administrative		620,793		593,457
Total		1,741,883		1,851,070
OPERATING INCOME		345,453		144,563
OTHER INCOME (EXPENSE):				
Interest income		17,272		6,437
Interest expense		(28,891)		(32,088)
Total		(11,619)		(25,651)
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES		333,834		118,912
(PROVISION FOR) BENEFIT FROM FEDERAL AND STATE INCOME TAXES		(84,150)		(29,583)
NET INCOME	\$	249,684	\$	89,329
NET INCOME PER SHARE, BASIC	\$	0.10	\$	0.04
NET INCOME PER SHARE, DILUTED	\$	0.10	\$	0.04
WEIGHTED AVERAGE SHARES, BASIC		2,454,116		2,454,116
WEIGHTED AVERAGE SHARES, DILUTED		2,454,116		2,459,697

Condensed Statements of Cash Flows (Unaudited)

	S	ix Months En	d June 30,		
CASH FLOWS FROM OPERATING ACTIVITIES:	2019			2018	
Net income	\$	249,684	\$	89,329	
Adjustments to reconcile net income to net cash					
provided from (used in) operating activities-					
Depreciation and amortization		207,725		226,007	
Provision for doubtful accounts, net change		-		1,000	
Provision for inventory obsolescence, net change		7,500		32,500	
Deferred taxes, net change		(7,616)		(10,405)	
Stock based compensation expense related to					
stock options		3,221		8,734	
Changes in operating assets and liabilities-					
Accounts receivable		(230,626)		(67,423)	
Inventories		(662,940)		(129,781)	
Income taxes receivable		90,629		39,988	
Prepaid expenses and other		(94,426)		(62,504)	
Deposits and other		62,883		253,893	
Accounts payable		109,760		32,511	
Customer deposits		120,330		(33,711)	
Accrued expenses		24,770		(65,885)	
Deferred revenue		16,657		(743)	
Net cash provided from (used in) operating activities		(102,449)		313,510	
CASH FLOWS FROM INVESTING ACTIVITIES:					
Purchases of property and equipment		(128,614)		(373,368)	
Net cash (used in) investing activities		(128,614)		(373,368)	
CASH FLOWS FROM FINANCING ACTIVITIES:					
Principal payments made on term loan		(22,156)		(21,293)	
Net cash (used in) financing activities		(22,156)		(21,293)	
NET (DECREASE) IN CASH		(253,219)		(81,151)	
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		2,788,327		2,669,455	
CASH AND CASH EQUIVALENTS, END OF PERIOD		2,535,108	\$	2,588,304	
SUPPLEMENTAL INFORMATION:					
Cash paid for interest	\$	28,349	\$	29,828	
Cash paid for income tax	\$		\$		

Contacts Sarah Struble Lifeloc Technologies, Inc. <u>http://www.lifeloc.com</u> (303) 431-9500